- Sugen's malignant glioma treatment SU101 has shown early promise in a Phase I dose-escalation trial. Of 24 patients who have completed their first cycle of therapy, 13 have continued into extended treatment based on stable disease or better, demonstrated by physical examination and magnetic resonance imaging. Two patients exhibited decreases in tumor cross-sectional area of 43% and 49% respectively. Another Phase I trial in poor-prognosis solid tumor patients has also started.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze